Essential Thrombocythemia Symptoms Diagnosis and Treatment

Essential thrombocythemia, or ET, is a rare blood cancer that affects platelet production ^3,8. It is a chronic disease that needs long-term monitoring ³.

Platelets are blood particles that help clots form ^7,8. With ET, bone marrow makes more platelets than the body needs ^5,8.

This change raises the risk of harmful clots and unusual bleeding ^1,8. However, many people have no symptoms when doctors first find ET ^2,3.

Doctors use blood tests, gene tests, and bone marrow findings to diagnose ET ^3,5. They must also rule out other causes of a high platelet count.

Treatment aims to prevent clots, limit bleeding, and ease symptoms. This guide explains warning signs, testing, treatment choices, and follow-up.

ET is a myeloproliferative neoplasm, also known as an MPN ^3,5. This blood cancer starts in blood-forming stem cells within bone marrow.

Doctors classify ET as a BCR::ABL1-negative MPN. This group also includes polycythemia vera and primary myelofibrosis.

ET causes abnormal growth of megakaryocytes within the marrow ^4,5. Megakaryocytes are large marrow cells that make platelets.

This growth causes a lasting increase in circulating platelets. Some platelets may also be larger than normal ⁸.

ET differs from reactive thrombocytosis ^6,8. Reactive thrombocytosis is a platelet increase caused by another disease or condition ⁸.

Doctors must separate these conditions before confirming ET. Reactive causes are more common than clonal marrow diseases in routine care.

About 90% of people with ET have a variant involving the JAK-STAT pathway. This pathway controls signals involved in blood cell growth ^1,4.

JAK2 variants occur in about 64% of patients. CALR variants occur in about 23%, while MPL variants occur in about 4%.

These variants involve genes with different roles; MPL proteins help activate signals that promote blood cell growth ^1,4. The active signals increase megakaryocyte and platelet production ⁴.

Most ET gene changes develop during a person’s life ⁸. Doctors call these acquired changes somatic variants ⁴.

Most cases do not pass from parents to children ⁴. Inherited family forms can occur, but they are less common ⁴.

Negative JAK2, CALR, and MPL results do not rule out ET. Up to 20% of patients may lack all three common variants.

The median age at diagnosis is about 59 years. A median represents the midpoint within a group.

ET can also affect younger adults. Large studies have included people diagnosed at age 18.

Women made up 63% and 65% of two large patient groups. However, ET can affect people of any sex ^3,6.

About 40% to 50% of patients have no symptoms when diagnosed ³. Doctors may find ET after a routine blood test shows thrombocytosis ³.

Thrombocytosis means the platelet count is higher than normal. When symptoms occur, they may include vasomotor symptoms ^3,6.

Symptoms may also result from a major clot or unusual bleeding ^2,3. The type and severity can differ between people.

Possible symptoms include the following:

Erythromelalgia is a small-vessel problem that affects the limbs. It most often involves the hands or feet.

ET can cause clots within arteries or veins. Reported complications include arterial clots in about 11% of patients.

Venous clots occur in about 7% of patients. The effects depend on where the blocked blood vessel is located.

An arterial clot may cause a transient ischemic attack, stroke, or heart attack ^2,8. A transient ischemic attack causes temporary stroke-like symptoms.

A deep vein clot may cause pain or swelling in one leg. Doctors call this condition deep vein thrombosis.

A clot can also travel to the lungs. This event is called a pulmonary embolism.

A pulmonary embolism may cause chest pain and difficulty breathing. Clots can also develop in veins within the abdomen.

Hemorrhage means heavy or serious bleeding. Hemorrhage has been reported in about 8% of people with ET.

Possible bleeding concerns include the following:

Bleeding occurs more often when platelet counts become very high. Extreme counts may cause acquired von Willebrand syndrome.

This syndrome reduces the activity of a protein needed for clotting. Therefore, bleeding can occur even when platelet levels are high.

Call emergency services or seek emergency care now for these warning signs:

If one leg becomes painful or swollen, contact a clinician for an assessment ^2,7. These symptoms can occur with a deep vein clot.

ET involves a persistent platelet count of at least 450 × 10⁹/L. However, a high platelet count alone cannot confirm ET ^3,6.

Doctors look for a pattern across several tests ^3,6. They also check whether another condition explains the increase.

Doctors may order a complete blood count when assessing ET ^1,3. The test measures platelets and other blood cell types.

Initial tests may include the following:

Doctors may also ask about symptoms and perform a physical examination ⁸. These findings help guide further testing.

A bone marrow biopsy is an important part of the diagnostic process. It helps separate ET from similar marrow disorders.

ET commonly causes an increased number of large, mature megakaryocytes. Their nuclei are often hyperlobulated, meaning they contain several sections.

These cells often form loose groups within the marrow. Dense groups and major marrow scarring are not typical findings.

Marrow findings matter when doctors consider prefibrotic myelofibrosis. This early marrow disease can resemble ET.

A biopsy also helps assess other marrow cell lines. ET generally lacks major increases in immature red or white blood cells.

Doctors may test blood or marrow for JAK2, CALR, and MPL variants ^3,5. Finding one supports the presence of an underlying MPN.

A positive result does not identify ET by itself. Other marrow cancers may carry the same variants.

Some patients test negative for all three common variants. Doctors may then look for another clonal marker.

Clonal means the abnormal cells came from one changed parent cell. Marrow findings remain important when common mutation tests are negative.

Many health problems can raise the platelet count. Doctors must rule out these causes before diagnosing ET.

Possible reactive causes include the following:

Platelet levels may improve after inflammation ends. Counts caused by iron deficiency may improve after iron replacement.

Doctors must also exclude other marrow diseases. These include polycythemia vera, prefibrotic myelofibrosis, and chronic myeloid leukemia.

Diagnosis requires compatible blood, marrow, clinical, and gene findings. It also requires excluding reactive causes and other myeloid cancers.

The main treatment goal is preventing harmful clots. Care may also limit bleeding and ease symptoms.

Doctors use four broad risk groups ³. These groups are very low, low, intermediate, and high risk ³.

Doctors consider several clotting risk factors:

Treatment risk groups help guide decisions about observation, antiplatelet therapy, and cytoreductive therapy ^1,3. Treatment should match each person’s health needs and risk level ³.

Low-dose aspirin is suggested for many people with ET. It may help lower the risk of thrombosis.

A suggested dose is 81 to 100 milligrams each day. A clinician should decide whether aspirin fits your care plan.

ET can cause bleeding as well as clotting. Very high platelet levels may lead to acquired von Willebrand syndrome.

This syndrome can increase bleeding despite the high platelet count. Tell the care team about active or recent bleeding before taking aspirin.

Do not start aspirin without guidance from your clinician. Ask whether your bleeding risk needs further assessment.

Selected patients may not need immediate platelet-lowering medicine ^3,7. Their plan may include observation and regular blood tests ^3,7.

Even during observation, ET can worsen over time if untreated ⁷. Report new clotting or bleeding concerns between planned visits.

Some treatment plans include anticoagulant therapy ³. The choice depends on the patient’s clinical situation.

Anticoagulant and aspirin plans require careful clinical review. The care team must consider both clotting and bleeding concerns.

Cytoreduction means using medicine to reduce blood cell production. Doctors advise this treatment for high-risk ET.

Doctors may also consider cytoreduction for intermediate-risk disease. Hydroxyurea is the preferred medicine for many patients ³.

One trial included 114 people at high risk for thrombosis. Participants were over 60 or had experienced a previous clot.

Hydroxyurea reduced arterial or venous clot events from 24% to 3.6%. The comparison group did not receive cytoreductive treatment.

Other platelet-lowering choices include the following medicines:

Drug choice should fit the individual patient and treatment goal ³. Regular blood tests help clinicians follow platelet levels ^3,8.

The procedure provides a fast reduction in platelet levels ⁷. Long-term care usually relies on medicines when platelet reduction is needed ⁷.

Current drug treatment aims to prevent clots, bleeding, and symptoms. Research has not shown that it prevents disease progression or extends survival.

People with ET need lifelong blood count monitoring ³. Regular visits allow clinicians to check platelet levels and symptoms ^3,8.

The care team also needs to review clotting and bleeding events. Treatment response and medicine concerns require ongoing attention.

Keep scheduled visits even when no symptoms occur. Many people have no symptoms when doctors first find ET ³.

Cardiovascular risks can increase clotting risk in ET. These include smoking, high blood pressure, diabetes, and high cholesterol.

If you smoke, ask your care team for help quitting. Work with clinicians to manage blood pressure, blood sugar, and cholesterol.

Ask how movement and weight goals fit your care plan. Lifestyle changes may form one part of ET management ³.

These steps do not replace prescribed treatment. They also do not replace regular blood tests and hematology visits.

ET can progress to post-ET myelofibrosis. This condition involves increasing scar-like tissue within bone marrow.

ET can also progress to acute myeloid leukemia. Both changes affect a small percentage of patients.

At a median 8.5 years, about 10% had developed myelofibrosis. About 3% had developed acute myeloid leukemia.

ET has the most favorable outlook among BCR::ABL1-negative MPNs. However, life expectancy may be slightly shorter than average ³.

Many people live for decades after diagnosis. Median survival exceeds 35 years among those diagnosed at age 40 or younger.

Age 60 or older and thrombosis are among the clinical factors assessed in ET ^1,3. Regular follow-up helps the care team watch for important changes ⁸.

Contact a clinician if blood tests continue showing raised platelet levels. A hematologist is a doctor who manages blood diseases.

Arrange a medical review for these non-emergency concerns:

ET is a chronic blood cancer that raises clotting and bleeding risks ^1,8. Diagnosis takes more than one high platelet result ^3,6.

Doctors combine blood counts, bone marrow findings, and mutation tests ^3,5. They must also rule out reactive thrombocytosis and other marrow diseases.

Treatment may include monitoring, aspirin, anticoagulants, or platelet-lowering medicine ^1,3. The right plan depends on each patient’s clotting and bleeding risks ^1,3.

Lifelong hematology care supports ongoing blood count monitoring ³. Managing cardiovascular risks also remains an important part of care.